Sclerotherapy of endometrioma and its impact on ovarian reserve – a narrative review

Česká verzia

Authors: Katarína Ivánková ; Hynek Heřman ; Jan Drahoňovský; Lucie Hájková Hympánová
Authors place of work: Ústav pro péči o matku a dítě, 3. LF UK, Praha
Published in the journal: Ceska Gynekol 2025; 90(2): 163-166
Category:
doi: https://doi.org/10.48095/cccg2025163

Summary

To summarize current knowledge on the use of sclerotherapy in the treatment of endometriomas and its effect on ovarian reserve. Endometriosis affects 10–15% of women of reproductive age. The presence and treatment of endometriomas influence ovarian reserve, and therefore the conception possibilities of patients. The management is further complicated by frequent recurrences. All standard surgical methods lead to a reduction in ovarian reserve. Current clinical research is focused on developing methods that minimize the reduction of ovarian reserve. Ethanol sclerotherapy is a relatively new alternative to the currently used surgical methods, mainly extirpation. It is not yet a standard procedure. This article aims to summarize the current knowledge regarding the use of sclerotherapy in the treatment of endometriomas and its effect on ovarian reserve. The studies included in this review article are based on PubMed and Scopus databases. According to published works, sclerotherapy is a relatively simple method that allows treating endometriomas without surgery and general anaesthesia if performed under ultrasound guidance. It has a similar recurrence rate as laparoscopic extirpation and does not lead to a greater reduction in ovarian reserve compared to the latter. Sclerotherapy can be performed trans-vaginally, trans-abdominally, or laparoscopically. This paper summarizes the current knowledge on the impact of sclerotherapy on ovarian reserve.

Keywords:

Endometriosis – endometrioma – sclerotherapy – anti-Müllerian hormone – ovarian reserve

Zdroje

1. Falcone T, Flyckt R. Clinical management of endometriosis. Obstet Gynecol 2018; 131 (3): 557–571. doi: 10.1097/AOG.0000000000002469.

2. Busacca M, Vignali M. Ovarian endometriosis: from pathogenesis to surgical treatment. Curr Opin Obstet Gynecol 2003; 15 (4): 321–326. doi: 10.1097/01.gco.0000084247.09900.4f.

3. Guo SW, Wang Y, Liu X et al. Laterality and asymmetry of endometriotic lesions. Fertil Steril 2008; 89 (1): 33–41. doi: 10.1016/j.fertnstert.2007.02.043.

4. Benaglia L, Somigliana E, Vercellini P et al. Endometriotic ovarian cysts negatively affect the rate of spontaneous ovulation. Hum Reprod 2009; 24 (9): 2183–2186. doi: 10.1093/humrep/ dep202.

5. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2020; 114 (6): 1151–1157. doi: 10.1016/j.fertnstert.2020.09.134.

6. Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril 2011; 95 (2): 747–750. doi: 10.1016/j.fertnstert.2010.10.011.

7. Anderson RA, Wallace WH. Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril 2013; 99 (6): 1469–1475. doi: 10.1016/j.fertnstert.2013.03.014.

8. Seo JW, Lee DY, Yoon BK et al. The age-related recurrence of endometrioma after conservative surgery. Eur J Obstet Gynecol Reprod Biol 2017; 208: 81–85. doi: 10.1016/j.ejogrb.2016.11.015.

9. Benaglia L, Somigliana E, Vighi V et al. Rate of severe ovarian damage following surgery for endometriomas. Hum Reprod 2010; 25 (3): 678–682. doi: 10.1093/humrep/dep464.

10. Busacca M, Vignali M. Endometrioma excision and ovarian reserve: a dangerous relation. J Minim Invasive Gynecol 2009; 16 (2): 142–148. doi: 10.1016/j.jmig.2008.12.013.

11. Becker CM, Bokor A, Heikinheimo O et al; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. 2022 [online]. Available from: https: //www.eshre.eu/guideline/endometriosis.

12. Younis JS, Shapso N, Ben-Sira Y et al. Endometrioma surgery-a systematic review and meta-analysis of the effect on antral follicle count and anti-Müllerian hormone. Am J Obstet Gynecol 2022; 226 (1): 33.e7–51.e7. doi: 10.1016/ j.ajog.2021.06.102. Erratum in: Am J Obstet Gynecol 2023; 229 (1): 88. doi: 10.1016/j.ajog. 2022.03.055.

13. Jee BC. Efficacy of ablation and sclerotherapy for the management of ovarian endometrioma: a narrative review. Clin Exp Reprod Med 2022; 49 (2): 76–86. doi: 10.5653/cerm.2021.05183.

14. Giampaolino P, Bifulco G, Di Spiezio Sardo A et al. Endometrioma size is a relevant factor in selection of the most appropriate surgical technique: a prospective randomized preliminary study. Eur J Obstet Gynecol Reprod Biol 2015; 195: 88–93. doi: 10.1016/j.ejogrb.2015.09.046.

15. Albanese G, Kondo KL. Pharmacology of sclerotherapy. Semin Intervent Radiol 2010; 27 (4): 391–399. doi: 10.1055/s-0030-1267848.

16. Ronsini C, Iavarone I, Braca E et al. The efficiency of sclerotherapy for the management of endometrioma: a systematic review and meta-analysis of clinical and fertility out- -comes. Medicina (Kaunas) 2023; 59 (9): 1643. doi: 10.3390/medicina59091643.

17. Miquel L, Liotta J, Pivano A et al. Ethanol endometrioma sclerotherapy: safety through 8 years of experience. Hum Reprod 2024; 39 (4): 733–741. doi: 10.1093/humrep/deae014.

18. Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis. Fertil Steril 2017; 108 (1): 117.e5–124.e5. doi: 10.1016/j.fertnstert.2017.05.015.

19. Kim GH, Kim PH, Shin JH et al. Ultrasound--guided sclerotherapy for the treatment of ovarian endometrioma: an updated systematic review and meta-analysis. Eur Radiol 2022; 32 (3): 1726–1737. doi: 10.1007/s00330-021-08270-5.

20. Azizova A, Ciftci TT, Gultekin M et al. Ethanol sclerotherapy in the management of ovarian endometrioma: technical considerations for catheter- and needle-directed sclerotherapy. Cardiovasc Intervent Radiol 2024; 47 (7): 891–900. doi: 10.1007/s00270-024-03694-0.

21. Vaduva CC, Dira L, Carp-Veliscu A et al. Ovarian reserve after treatment of ovarian endometriomas by ethanolic sclerotherapy compared to surgical treatment. Eur Rev Med Pharmacol Sci 2023; 27 (12): 5575–5582. doi: 10.26355/eurrev_202306_32795.

22. Garcia-Tejedor A, Martinez-Garcia JM, Candas B et al. Ethanol sclerotherapy versus laparoscopic surgery for endometrioma treatment: a prospective, multicenter, cohort pilot study. J Minim Invasive Gynecol 2020; 27 (5): 1133–1140. doi: 10.1016/j.jmig.2019.08.036.

23. Koo JH, Lee I, Han K et al. Comparison of the therapeutic efficacy and ovarian reserve between catheter-directed sclerotherapy and surgical excision for ovarian endometrioma. Eur Radiol 2021; 31 (1): 543–548. doi: 10.1007/s00330-020-07111-1.

24. Ghasemi Tehrani H, Tavakoli R, Hashemi M et al. Ethanol sclerotherapy versus laparoscopic surgery in management of ovarian endometrioma; a randomized clinical trial. Arch Acad Emerg Med 2022; 10 (1): e55. doi: 10.22037/aaem.v10i1.1636.

25. Huang L, Chang MY, Shiau CS et al. Changes in anti-Müllerian hormone after ultrasound guided aspiration and ethanol sclerotic therapy of ovarian cyst. Taiwan J Obstet Gynecol 2021; 60 (3): 509–512. doi: 10.1016/j.tjog.2021.03.021.

26. De Cicco Nardone A, Carfagna P et al. Laparoscopic ethanol sclerotherapy for ovarian endometriomas: preliminary results. J Minim Invasive Gynecol 2020; 27 (6): 1331–1336. doi: 10.1016/j.jmig.2019.09.792.

27. Crestani A, Merlot B, Dennis T et al. Impact of laparoscopic sclerotherapy for ovarian endometriomas on ovarian reserve. J Minim Invasive Gynecol 2023; 30 (1): 32–38. doi: 10.1016/j.jmig.2022.10.001.

ORCID autorů

K. Ivánková 0009-0003-6292-7282

H. Heřman 0000-0001-5732-3159

L. Hájková Hympánová 0000-0002-9002-9231

Doručeno/Submitted: 13. 9. 2024

Přijato/Accepted: 10. 10. 2024

MUDr. Katarína Ivánková

Ústav pro péči o matku a dítě

3. LF UK

Podolské nábřeží 157/36

147 00 Praha

katarina.ivankova@upmd.eu